Los Angeles Biotechnology Network
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ June 10, 2023 ] Graduating senior lights the path for transfer students – through her award-winning research and mentoring Los Angeles Biotech News
  • [ June 10, 2023 ] Postdoctoral Scientist – Karsh Division of Gastroenterology and Hepatology – Part-Time – CEDARS-SINAI – Los Angeles, CA Los Angeles Biotech Jobs
  • [ June 10, 2023 ] Adcomm votes yes on Leqembi full OK; Merck brings first IRA lawsuit; Special: LGBTQ+ leaders; Best-paying biopharma jobs; and more Los Angeles Biotech News
  • [ June 10, 2023 ] Scientist, Cell Biology – Thermo Fisher Scientific – West Hills, CA Los Angeles Biotech Jobs
  • [ June 10, 2023 ] Security Officer – Biotechnology Company – Allied Universal® – Oceanside, CA Los Angeles Biotech Jobs
HomeLos Angeles Biotech NewsSTAT Plus: Study of experimental heart drug from Cytokinetics, Amgen meets goal — but still disappoints

STAT Plus: Study of experimental heart drug from Cytokinetics, Amgen meets goal — but still disappoints

October 8, 2020 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on STAT Plus: Study of experimental heart drug from Cytokinetics, Amgen meets goal — but still disappoints
Cytokinetics and Amgen said their study of an experimental heart drug achieved its main goal, but the treatment effect was marginal.

Click to view original post

Previous

New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function

Next

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Follow/Subscribe

POST A JOB
Tweets by LABioNetwork

Copyright © 2021 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered